Top Penny Stocks to Watch Now: Soligenix, Catheter Precision, and Wellgistics Health

Three penny stocks to watch on August 19, 2025, are Soligenix (SNGX), Catheter Precision (VTAK), and Wellgistics Health (WGRX). They were identified using TipRanks' Penny Stock Screener tool based on high Dollar Volume. Soligenix's stock price surged 78% after FDA orphan drug designation for its treatment of Behcet's Disease. Catheter Precision's LockeT was registered and approved in the UK, while Wellgistics Health terminated its equity line of credit and launched a blockchain-based payments program.

As the financial markets continue to evolve, investors are always on the lookout for promising opportunities. On August 19, 2025, three penny stocks have caught the attention of investors using TipRanks' Penny Stock Screener tool based on high Dollar Volume: Soligenix (SNGX), Catheter Precision (VTAK), and Wellgistics Health (WGRX).

Soligenix (SNGX)

Soligenix (SNGX) experienced a significant surge in its stock price, rising by 78% following the FDA's orphan drug designation for its treatment of Behçet's Disease. The designation was granted to dusquetide, the active ingredient in SGX945, which has demonstrated promising results in clinical trials. The FDA's decision provides Soligenix with seven years of U.S. market exclusivity upon final approval, along with financial and regulatory benefits. This designation is a significant milestone for Soligenix, positioning it strongly in the rare disease market [1].

Catheter Precision (VTAK)

Catheter Precision (VTAK) also made headlines with the registration and approval of its LockeT in the UK. The approval of LockeT, a catheter-based system designed for minimally invasive procedures, underscores the company's advancements in medical technology. This achievement is likely to boost investor confidence in the company's future prospects [2].

Wellgistics Health (WGRX)

Wellgistics Health (WGRX) has been making strategic moves to enhance its financial stability. The company terminated its equity line of credit and launched a blockchain-based payments program. These moves indicate a commitment to improving operational efficiency and potentially reducing costs. This shift in strategy may attract investors looking for companies that are actively addressing financial and operational challenges [3].

These three penny stocks are worth monitoring for investors seeking high Dollar Volume opportunities. While Soligenix's FDA designation is a significant catalyst, investors should also consider the broader market conditions and the companies' individual financial health before making investment decisions.

References

[1] https://www.tipranks.com/news/company-announcements/soligenix-gains-fda-orphan-drug-designation-for-dusquetide
[2] https://www.biospace.com/press-releases/fda-grants-soligenix-orphan-drug-designation-for-the-treatment-of-behcets-disease-after-reviewing-recent-phase-2-clinical-study-results
[3] https://www.tipranks.com/news/company-announcements/soligenix-gains-fda-orphan-drug-designation-for-dusquetide